FDA proposes fast-track program for medical devices

The FDA is proposing expedited PMA approval of devices that would meet an unmet medical need for severe conditions.

The new program, referred to as Expedited Access PMA, or EAP, aims to reduce time spent on product development as well as time spent on premarket product review. "EAP is not a new pathway to market, but rather a collaborative approach to facilitate product development under the agency's existing regulatory authorities," the FDA said in a statement. The agency will continue to apply the same standards for approval when reviewing a device under the program.

"We are excited to offer a proposed program for expedited access for certain high-risk medical devices," said CDRH Director Jeffrey Shuren in a statement. "The program allows manufacturers to engage early and often with the agency. We expect most devices that enter this program will be in the preclinical trial phase."

To be eligible for the program, a device must:

  • be intended to treat or diagnose a life-threatening or irreversibly debilitating disease or condition;
  • be the only technology to treat or diagnose the condition; offer a "clinically meaning advantage" over approved technologies or approved alternative; or its availability must be in the patient's best interest; and 
  • have an FDA-approved data development plan.

In another draft guidance released today, "Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval," the FDA discussed the factors it takes into account when considering the issue and gave examples of situations where post-approval studies may be appropriate at the time of PMA approval.

Post-approval studies, quality systems regulation and other postmarket controls "should be considered a mechanism to reduce the extent of the premarket data for PMA applications, while still ensuring that statutory standard for premarket approval is met," the draft guidance states.

The guidance lists several instances when post-approval studies are called for. For example, in the case of mature, well-understood device types, the agency is more likely to employ postmarket as opposed to premarket studies because there is less uncertainty about their safety and effectiveness.

The results of postmarket studies can also be used to modify approved labeling, to confirm a devices' approved use in an intended population, to assess long-term performance and rare adverse events, and confirm bench data.

Another interesting use of postmarket studies listed was to "confirm mitigation effectiveness for a known risk in a post-approval study." This can occur when a new safety risk appears that was not strongly considered by the FDA at the time of approval.

For example, the draft guidance says the FDA worked with a firm to develop software for predicting implant failure after another company issued a recall for a similar implant. Due to the public health need, the FDA did not require clinical data to support the new software feature prior to approval. Instead the agency used modeling and previously published data to support PMA approval, and a postmarket study was done to collect clinical data on the new software in a timely fashion.

The agency stressed that the extent to which it will allow postmarket data in lieu of premarket data is influenced by ability to mandate post-approval studies as a condition of PMA approval and withdraw PMA approval if it later determines that there is not a "reasonable assurance that the device is safe or effective under the conditions of used prescribed."

The FDA has the authority to require postmarket studies as a condition of PMA approval and can withdraw a PMA if firms do not follow through, or if the postmarket data cast doubt on the device's safety and effectiveness, the guidance stressed.

In spite of those warnings, the guidance appears designed to assist firms as they navigate the PMA approval process. It advices firms to use the agency's pre-submission process to if they believe data previously required in a premarket submission should be collected postmarket or not at all.

Since both documents are draft guidance, stakeholders can submit comments on them to the FDA.

- read the release